Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer.
Endocrine therapies targeting the ER represent one of the most successful anticancer …

Endocrine therapy is a valuable option for the treatment of postmenopausal women with
estrogen receptor (ER)-positive breast cancer due to its demonstrated efficacy and favorable …

Abstract Learning Objectives After completing this course, the reader will be able to: Explain
the possible role of alternate growth factor signaling pathways in the development of …

Hormonal therapy, such as estrogen-targeting therapy, has undergone remarkable
development in recent several years, using drugs such as LH–RH agonists, new SERMs …

Endocrine therapy of breast cancer is perhaps the oldest form of effective and well-tolerated
targeted cancer systemic treatment, in both the adjuvant and metastatic disease settings …

The development of endocrine therapies has transformed the treatment of patients with
breast cancer. The shift from ablative surgery and aggressive chemotherapies to more …

Endocrine therapy (ET) constitutes the usual first-line of therapy for patients in the treatment
of metastatic hormone receptor-positive breast cancer. Unfortunately, not all patients …

Endocrine therapy resistance invariably develops in advanced estrogen receptor-positive
(ER+) breast cancer, but the underlying mechanisms are largely unknown. We have …

Endocrine therapies for breast cancer have been used for more than a century. The concept
that changing the hormonal balance of the patient with breast cancer could lead to changes …

Endocrine therapy has led to a significant improvement in outcomes for women with
estrogen receptor–positive (ER+) breast cancer. Current questions in the adjuvant setting …